Table 2.
Treatment strategies
| Pulmonary embolism |
Deep vein thrombosis |
Odds ratio (95% CI) / P value |
|
|---|---|---|---|
| Patients, N | 14 | 9 | |
| Duration of therapy, | |||
| Mean days (SD) | 260 ± 254 | 243 ± 195 | P = 0.867 |
| Median days (IQR) | 171 (111–335) | 177 (86–475) | P = 0.999 |
| Initial therapy, | |||
| Unfractionated heparin | 2 (14%) | 0 | – |
| Low-molecular-weight heparin | 10 (71%) | 9 (100%) | – |
| Mean LMWH dose (IU/kg/day) | 132 ± 50 | 151 ± 59 | P = 0.474 |
| LMWH doses < 100 IU/kg/day | 4 (29%) | 2 (22%) | 2.33 (0.31–17.55) |
| Rivaroxaban | 1 (7%) | 0 | – |
| Inferior vena cava filter (without anticoagulant therapy) | 1 (7%) | 0 | – |
| Long-term therapy, | 13 | 9 | |
| Low-molecular-weight heparin | 7 (54%) | 6 (67%) | 0.58 (0. 10-3.40) |
| Mean LMWH dose (IU/kg/day) | 135 ± 35 | 119 ± 43 | P = 0.491 |
| LMWH < 100 IU/kg/day | 1 (8%) | 2 (22%) | 0.27 (0.02–3.52) |
| Vitamin K antagonists | 5 (38%) | 3 (33%) | 1.25 (0. 21-7.41) |
| Rivaroxaban | 1 (8%) | 0 | – |
| No anticoagulant drugs | 0 | 0 | – |
Abbreviations: SD standard deviation, IQR interquartile range, LMWH low-molecular-weight heparin, IU international units, 95%CI, 95% confidence intervals